About Adgero Biopharma
Adgero Biopharma is a company based in Princeton (United States) founded in 2012 was acquired by DelMar Pharmaceuticals in June 2020. Adgero Biopharma has raised $5.52 million across 5 funding rounds from investors including HHS, Shanghai Fudan Zhangjiang Bio-Pharmaceutical Co and DelMar Pharmaceuticals. Adgero Biopharma operates in a competitive market with competitors including PhotoPharmics, CranioVation, Lumeda, Illumi Medical and SpectraCure, among others.
- Headquarter Princeton, United States
-
Sectors
HealthcareTechnology
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$5.52 M (USD)
in 5 rounds
-
Latest Funding Round
$225 K (USD), Grant
Jul 17, 2020
-
Investors
HHS
& 2 more
-
Employee Count
Not available
-
Acquired by
DelMar Pharmaceuticals
(Jun 10, 2020)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Adgero Biopharma
Unlock access to complete
Unlock access to complete
Funding Insights of Adgero Biopharma
Adgero Biopharma has successfully raised a total of $5.52M across 5 strategic funding rounds. The most recent funding activity was a Grant round of $225 thousand completed in July 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Adgero Biopharma
Adgero Biopharma has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include HHS, Shanghai Fudan Zhangjiang Bio-Pharmaceutical Co and DelMar Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked | |
|
Photosensitizers and nano-formulations for cancer treatments are developed.
|
Locked | Locked | Locked | |
|
Drug candidates targeting orphan cancer indications are developed.
|
Locked | Locked | Locked |
Investor details for Adgero Biopharma
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Adgero Biopharma
Investment portfolio details for Adgero Biopharma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Adgero Biopharma
Detailed financials for Adgero Biopharma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Adgero Biopharma Comparisons
Peer comparison for Adgero Biopharma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Adgero Biopharma
Adgero Biopharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as PhotoPharmics, CranioVation, Lumeda, Illumi Medical and SpectraCure, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Non-invasive phototherapy for Parkinson's disease is developed.
|
|
| Locked | Locked | Locked |
Minimally invasive devices for brain tumor treatment are provided.
|
|
| Locked | Locked | Locked |
Photodynamic therapy device for lung cancer treatment is developed.
|
|
| Locked | Locked | Locked |
Photodynamic therapy devices for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Developer of Interstitial photo dynamic therapy for solid tumours
|
Detailed competitors of Adgero Biopharma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Adgero Biopharma
Complete news archive for Adgero Biopharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Adgero Biopharma
Adgero Biopharma was founded in 2012 and raised its 1st funding round 3 years after it was founded.
Adgero Biopharma is headquartered in Princeton, United States. It is registered at Princeton, New Jersey, United States.
Adgero Biopharma is a funded company, having raised a total of $5.52M across 5 funding rounds to date.
Adgero Biopharma was founded in 2012 in Princeton, United States, within the biopharmaceutical sector. Focus is placed on advancing photodynamic therapy for patients with cutaneous metastatic breast cancer. The treatment system incorporates a laser light source, a light delivery device, and the drug Rostaporfin. Operations center on developing and refining this therapy to address unmet needs in oncology care.
Adgero Biopharma's top competitors include PhotoPharmics, ImPact Biotech and CranioVation.
Adgero Biopharma has 3 investors. Key investors include HHS, Shanghai Fudan Zhangjiang Bio-Pharmaceutical Co, and DelMar Pharmaceuticals.